rilonacept regeneron (previously arcalyst)
regeneron uk limited - rilonacept - criopirina periódicas asociadas a síndromes - inmunosupresores - rilonacept regeneron está indicado para el tratamiento de los síndromes periódicos cryopyrin asociada (caps) con síntomas severos, incluyendo familiar síndrome inflamatorio auto frío (fcas) y síndrome de muckle-wells (mws), en adultos y niños de 12 años y mayores.
regeneron solucion oral
cdi - solución oral
libtayo
regeneron ireland designated activity company (dac) - cemiplimab - carcinoma, célula escamosa - agentes antineoplásicos - cutaneous squamous cell carcinomalibtayo as monotherapy is indicated for the treatment of adult patients with metastatic or locally advanced cutaneous squamous cell carcinoma (mcscc or lacscc) who are not candidates for curative surgery or curative radiation. basal cell carcinomalibtayo as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic basal cell carcinoma (labcc or mbcc) who have progressed on or are intolerant to a hedgehog pathway inhibitor (hhi). non-small cell lung cancerlibtayo as monotherapy is indicated for the first-line treatment of adult patients with non-small cell lung cancer (nsclc) expressing pd-l1 (in ≥ 50% tumour cells), with no egfr, alk or ros1 aberrations, who have:locally advanced nsclc who are not candidates for definitive chemoradiation, ormetastatic nsclc. libtayo in combination with platinum‐based chemotherapy is indicated for the first‐line treatment of adult patients with nsclc expressing pd-l1 (in ≥ 1% of tumour cells), with no egfr, alk or ros1 aberrations, who have:locally advanced nsclc who are not candidates for definitive chemoradiation, ormetastatic nsclc. cervical cancerlibtayo as monotherapy is indicated for the treatment of adult patients with recurrent or metastatic cervical cancer and disease progression on or after platinum-based chemotherapy.
dupixent®
sanofi - aventis groupe francia - dupilumab 300 mg - solucion inyectable - cada jeringuilla precargada contiene (a): dupilumab 300 mg
eylia® solución para inyección intravítrea
bayer ag alemania - aflibercept 40,00 mg/ml - soluciÓn inyectable - cada 1 ml contiene: aflibercept 40,00 mg
eylia 40mg/ml solucion inyectable
bayer s.a. - droguerÍa - aflibercept - solucion inyectable - 40mg/ml - por - - antineovascularisation agents
eylia 40 mg/ml solucion para inyeccion intravitrea en jeringa prellenada
bayer, s.a. - aflibercept - solucion - 40 mg/ ml
eylia 40 mg/ml solucion para inyeccion intravitrea
bayer, s.a. - aflibercept - solucion - 40 mg/ ml
dupixent® 200 mg / 1.14 ml
sanofi - aventis groupe francia - dupilumab 200 mg - soluciÓn inyectable - cada jeringuilla precargada contiene (a): dupilumab 200 mg
lancome absolue creme fondante regenerante illuminatrice - crema regenerante iluminadora - rostro
l'oreal chile s.a. - sin formulas